CD40L-mediated inhibition of NF-kappaB in CA46 Burkitt lymphoma cells promotes apoptosis

References

• Clark E A, Ledbetter J A. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci USA 1986; 83: 4494–4498
   PubMed Web of Science ®Google Scholar
• Zhu F B, Wang S Y, Zhu J F, Zhang Y W, Lin Y J. Down-regulation of expression of survivin and induction of apoptosis in the human Burkitt lymphomas cells by ligation of CD40-CD40L. Zhonghua Yi Xue Za Zhi 2006; 86: 2716–2720
   PubMedGoogle Scholar
• Laskov R, Berger N, Horwitz M S. Differential effects of tumor necrosis factor-alpha and CD40L on NF-κB inhibitory proteins IkappaBalpha, beta and epsilon and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cells. Eur Cytokine Netw 2005; 16: 267–276
   PubMed Web of Science ®Google Scholar
• Vyth-Dreese F A, Boot H, Dellemijn T A, Majoor D M, Oomen L C, Laman J D, et al. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 1998; 94: 580–586
   PubMed Web of Science ®Google Scholar
• Johnson P W, Watt S M, Betts D R, Davies D, Jordan S, Norton A J, et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 1993; 82: 1848–1857
   PubMed Web of Science ®Google Scholar
• Funakoshi S, Taub D D, Asai O, Hirano A, Ruscetti F W, Longo D L, et al. Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis. Leuk Lymphoma 1997; 24: 187–199
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans H C, Beverstock G C, Mollevanger P, Wessels H W, Hoogendoorn E, Willemze R, et al. Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. Blood 1994; 84: 3134–3141
   PubMed Web of Science ®Google Scholar
• Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999; 93: 1992–2002
   PubMed Web of Science ®Google Scholar
• Hollenbaugh D, Grosmaire L S, Kullas C D, Chalupny N J, Braesch-Andersen S, Noelle R J, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992; 11: 4313–4321
   PubMed Web of Science ®Google Scholar
• Zhu N, Ramirez L M, Lee R L, Magnuson N S, Bishop G A, Gold M R. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol 2002; 168: 744–754
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997; 9: 330–337
   PubMed Web of Science ®Google Scholar
• Funakoshi S, Longo D L, Beckwith M, Conley D K, Tsarfaty G, Tsarfaty I, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787–2794
   PubMed Web of Science ®Google Scholar
• Funakoshi S, Longo D L, Murphy W J. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J Immunother Emphasis Tumor Immunol 1996; 19: 93–101
   PubMed Web of Science ®Google Scholar
• Szocinski J L, Khaled A R, Hixon J, Halverson D, Funakoshi S, Fanslow W C, et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 2002; 100: 217–223
   PubMed Web of Science ®Google Scholar
• Ghetie M A, Picker L J, Richardson J A, Tucker K, Uhr J W, Vitetta E S. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 1994; 83: 1329–1336
   PubMed Web of Science ®Google Scholar
• Dadgostar H, Cheng G. An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activation but is dispensable for c-Jun N-terminal kinase signaling. J Biol Chem 1998; 273: 24775–24780
   PubMed Web of Science ®Google Scholar
• Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 2005; 5: 435–445
   PubMed Web of Science ®Google Scholar
• Liou H C, Sha W C, Scott M L, Baltimore D. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994; 14: 5349–5359
   PubMed Web of Science ®Google Scholar
• Koyama M, Spicer S S, Schulte B A. Distribution of IkappaB proteins in gastric mucosa and other organs of mouse and gerbil. J Histochem Cytochem 2000; 48: 191–200
   PubMed Web of Science ®Google Scholar
• Budde L M, Wu C, Tilman C, Douglas I, Ghosh S. Regulation of IkappaBbeta expression in testis. Mol Biol Cell 2002; 13: 4179–4194
   PubMed Web of Science ®Google Scholar
• Grumont R J, Rourke I J, O'Reilly L A, Strasser A, Miyake K, Sha W, et al. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-κB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 1998; 187: 663–674
   PubMed Web of Science ®Google Scholar
• Morris A E, Remmele R L, Jr, Klinke R, Macduff B M, Fanslow W C, Armitage R J. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem 1999; 274: 418–423
   PubMed Web of Science ®Google Scholar
• Armitage R J, Maliszewski C R, Alderson M R, Grabstein K H, Spriggs M K, Fanslow W C. CD40L: a multi-functional ligand. Semin Immunol 1993; 5: 401–412
   PubMedGoogle Scholar
• Alexandroff A B, Robins R A, Murray A, James K. Tumour immunology: false hopes–new horizons?. Immunol Today 1998; 19: 247–250
   PubMedGoogle Scholar
• Young L S, Eliopoulos A G, Gallagher N J, Dawson C W. CD40 and epithelial cells: across the great divide. Immunol Today 1998; 19: 502–506
   PubMedGoogle Scholar
• Ghamande S, Hylander B L, Oflazoglu E, Lele S, Fanslow W, Repasky E A. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001; 61: 7556–7562
   PubMed Web of Science ®Google Scholar
• Hirano A, Longo D L, Taub D D, Ferris D K, Young L S, Eliopoulos A G, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93: 2999–3007
   PubMed Web of Science ®Google Scholar
• Gordon J. CD40 and its ligand: central players in B lymphocyte survival, growth, and differentiation. Blood Rev 1995; 9: 53–56
   PubMed Web of Science ®Google Scholar
• Pham L V, Tamayo A T, Yoshimura L C, Lo P, Terry N, Reid P S, et al. A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-κB and autonomous cell growth in B cell lymphomas. Immunity 2002; 16: 37–50
   PubMed Web of Science ®Google Scholar
• Metkar S S, Manna P P, Anand M, Naresh K N, Advani S H, Nadkarni J J. CD40 Ligand–an anti-apoptotic molecule in Hodgkin's disease. Cancer Biother Radiopharm 2001; 16: 85–92
   PubMed Web of Science ®Google Scholar
• Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280–288
   PubMed Web of Science ®Google Scholar
• May M J, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80–88
   PubMedGoogle Scholar
• Zarnegar B, He J Q, Oganesyan G, Hoffmann A, Baltimore D, Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-κB activation pathways. Proc Natl Acad Sci USA 2004; 101: 8108–8113
   PubMed Web of Science ®Google Scholar
• Sakata N, Hamelmann E, Siadak A W, Terada N, Gerwins P, Aruffo A, et al. Differential regulation of CD40-mediated human B cell responses by antibodies directed against different CD40 epitopes. Cell Immunol 2000; 201: 109–123
   PubMed Web of Science ®Google Scholar
• Brouwer R E, Hoefnagel J, Borger van Der Burg B, Jedema I, Zwinderman K H, Starrenburg I C, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol 2001; 115: 298–308
   PubMed Web of Science ®Google Scholar
• Dilloo D, Brown M, Roskrow M, Zhong W, Holladay M, Holden W, et al. CD40 ligand induces an antileukemia immune response in vivo. Blood 1997; 90: 1927–1933
   PubMed Web of Science ®Google Scholar
• Hurwitz A A, Kwon E D, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000; 12: 589–596
   PubMed Web of Science ®Google Scholar
• Wu T C, Huang A Y, Jaffee E M, Levitsky H I, Pardoll D M. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995; 182: 1415–1421
   PubMed Web of Science ®Google Scholar
• Weinberg A D, Rivera M M, Prell R, Morris A, Ramstad T, Vetto J T, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000; 164: 2160–2169
   PubMed Web of Science ®Google Scholar
• Liu X, Bai X F, Wen J, Gao J X, Liu J, Lu P, et al. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med 2001; 194: 1339–1348
   PubMed Web of Science ®Google Scholar
• Stamenkovic I, Clark E A, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989; 8: 1403–1410
   PubMed Web of Science ®Google Scholar
• Thomas W D, Smith M J, Si Z, Hersey P. Expression of the co-stimulatory molecule CD40 on melanoma cells. Int J Cancer 1996; 68: 795–801
   PubMed Web of Science ®Google Scholar
• Airoldi I, Lualdi S, Bruno S, Raffaghello L, Occhino M, Gambini C, et al. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40 + neuroblastoma cells undergo apoptosis following interaction with CD40L. Br J Cancer 2003; 88: 1527–1536
   PubMed Web of Science ®Google Scholar